Literature DB >> 11296697

Mitochondria in steatohepatitis.

D Pessayre1, A Berson, B Fromenty, A Mansouri.   

Abstract

For the first time in history, populations in affluent countries may concomitantly indulge in rich food and physical idleness. Various combinations of obesity, diabetes, and hypertriglyceridemia, with insulin resistance as the common feature, cause hepatic steatosis, which can trigger necroinflammation and fibrosis. Patients with "primary" steatohepatitis exhibit ultrastructural mitochondrial lesions, decreased activity of respiratory chain complexes, and have impaired ability to resynthesize ATP after a fructose challenge. Mitochondria play a major role in fat oxidation and energy production but also leak reactive oxygen species (ROS) and are the main cellular source of ROS. In patients with steatosis, mitochondrial ROS may oxidize hepatic fat deposits, as suggested in animal models. Lipid peroxidation products impair the flow of electrons along the respiratory chain, which may cause overreduction of respiratory chain components, further increasing mitochondrial ROS formation and lipid peroxidation. Another vicious circle could involve ROS-induced depletion of antioxidants, impairing ROS inactivation. Blood vitamin E is decreased in some obese children with steatohepatitis, and serum transaminases improve after vitamin E supplementation. Steatohepatitis is also caused by alcohol abuse, drugs, and other causes. In "secondary" steatohepatitis, mitochondrial ROS formation is further increased as the causative disease itself directly increases ROS or first impairs respiration, which secondarily increases mitochondrial ROS formation. This "second hit" could cause more lipid peroxidation, cytokine induction, Fas ligand induction, and fibrogenesis than in primary steatohepatitis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11296697     DOI: 10.1055/s-2001-12929

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  75 in total

1.  Sonographic fatty liver and hepatitis B virus carrier status: synergistic effect on liver damage in Taiwanese adults.

Authors:  Yu-Cheng Lin; Shu-Tin Hsiao; Jong-Dar Chen
Journal:  World J Gastroenterol       Date:  2007-03-28       Impact factor: 5.742

Review 2.  Mitochondrial energetics and insulin resistance.

Authors:  Anthony E Civitarese; Eric Ravussin
Journal:  Endocrinology       Date:  2008-01-17       Impact factor: 4.736

Review 3.  Laboratory approach to mitochondrial diseases.

Authors:  D Parra; A González; C Mugueta; A Martínez; I Monreal
Journal:  J Physiol Biochem       Date:  2001-09       Impact factor: 4.158

Review 4.  Nonalcoholic fatty liver disease: a clinical review.

Authors:  David A Sass; Parke Chang; Kapil B Chopra
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

5.  The clinical biochemistry of obesity.

Authors:  Ken A Sikaris
Journal:  Clin Biochem Rev       Date:  2004-08

6.  Comparative studies of early liver dysfunction in senescence-accelerated mouse using mitochondrial proteomics approaches.

Authors:  Yashu Liu; Jintang He; Shaoyi Ji; Qingsong Wang; Hai Pu; Tingting Jiang; Lingyao Meng; Xiuwei Yang; Jianguo Ji
Journal:  Mol Cell Proteomics       Date:  2008-05-29       Impact factor: 5.911

Review 7.  Non-alcoholic fatty liver disease: an emerging pathological spectrum.

Authors:  Elie Serge Zafrani
Journal:  Virchows Arch       Date:  2003-12-18       Impact factor: 4.064

Review 8.  Managing nonalcoholic fatty liver disease: recommendations for family physicians.

Authors:  Ignazio Grattagliano; Piero Portincasa; Vincenzo O Palmieri; Giuseppe Palasciano
Journal:  Can Fam Physician       Date:  2007-05       Impact factor: 3.275

Review 9.  Is hepatic lipogenesis fundamental for NAFLD/NASH? A focus on the nuclear receptor coactivator PGC-1β.

Authors:  Simon Ducheix; Maria Carmela Vegliante; Gaetano Villani; Nicola Napoli; Carlo Sabbà; Antonio Moschetta
Journal:  Cell Mol Life Sci       Date:  2016-08-13       Impact factor: 9.261

10.  Curcumin prevents the non-alcoholic fatty hepatitis via mitochondria protection and apoptosis reduction.

Authors:  Long Wang; Yisong Lv; Huixiang Yao; Li Yin; Jianhui Shang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.